Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Intra-Cellular Therapies Inc.

www.intracellulartherapies.com

Latest From Intra-Cellular Therapies Inc.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Drug Review Drug Approval Standards

Finance Watch: Expect A Busy First Half For 2020 IPOs

Public Company Edition: At the J.P. Morgan Healthcare Conference and Biotech Showcase it was noted that the US IPO market is likely to be less active in the second half of the year as election risk chills investment. Also, Apellis leads recent follow-on offerings.

Financing Business Strategies

Keeping Track Of The US FDA's Final Novel Approvals, CRLs Of 2019

The latest news on novel drug approvals and complete response letters from our US FDA Performance Tracker.

US FDA Performance Tracker Approvals

US FDA Ends 2019 With Second-Highest Approval Count After Second-Half Rebound

CDER's 48 novel agents, including 35 in the second half of the year, marks the second-highest novel approval count in the contemporary era.

Approvals Drug Review
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Intra-Cellular Therapies Inc.
  • Senior Management
  • Sharon Mates, PhD, Chmn. & CEO
    Lawrence J Hineline, VP, Fin. & CFO
    Allen A Fienberg, PhD, VP, Bus. Dev.
    Robert E Davis, PhD, SVP, CSO
    Andrew Satlin, MD, EVP, CMO
    Mark Neumann, EVP, Chief Commercial Officer
  • Contact Info
  • Intra-Cellular Therapies Inc.
    Phone: (646) 440-9333
    430 East 29th St.
    Ste. 900
    New York, NY 10016
    USA
UsernamePublicRestriction

Register